ALGIPRO - Alginates by Production Scale Fermentation and Epimerisation

ALGIPRO - 通过生产规模发酵和差向异构化生产海藻酸盐

• 批准号: 102148
• 金额: $ 54.53万
• 依托单位: CENTRE FOR PROCESS INNOVATION LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2016
• 资助国家: 英国
• 起止时间: 2016 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=102148
• 关键词: ALGIPRO; Alginates; Production; Scale; Fermentation

The project, ALGIPRO, is an innovative collaborative effort between Norway and the UK. It will translate over 20 years of academic research into an industrial scale production process for alginates. The Centre for Process Innovation Ltd. (UK) is leading the scale-up based on development by SINTEF (Norway). AlgiPharma AS (Norway) will use the product as the Active Pharmaceutical Ingredient in its development of medicines for cystic fibrosis, COPD and chronic wounds. FMC Biopolymer (UK, Norway) will market the product in existing and new applications within the food and pharmaceutical markets.If successful ALGIPRO will facilitate the introduction of novel medicinal products to the market that will ease patient suffering and potentially reduce healthcare costs. In addition it will be a new tool in fighting multi-drug resistant bacteria.

ALGIPRO项目是挪威和英国之间的一项创新合作。它将把20多年的学术研究转化为海藻酸盐的工业规模生产过程。工艺创新中心有限公司（英国）正在SINTEF（挪威）开发的基础上领导规模扩大。AlgiPharma AS（挪威）将使用该产品作为其开发囊性纤维化，COPD和慢性伤口药物的活性药物成分。FMC Biopolymer（英国，挪威）将在食品和药品市场的现有和新的应用中销售该产品。如果成功，ALGIPRO将促进新的医药产品推向市场，这将减轻患者的痛苦，并可能降低医疗保健成本。此外，它将成为对抗多重耐药细菌的新工具。